Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

NCT03118947 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT03118947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03118947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 23, 2017
Completion date
February 25, 2019
Enrollment
79 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

agitation and aggression in alzheimer's disease